SGLT-2i and ARB combination therapy in patients with T2DM and nocturnal hypertension
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Hypertension; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SACRA
- 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 26 May 2017 Status changed from not yet recruiting to recruiting.
- 05 Dec 2016 New trial record